Gene transfer to the CNS using recombinant adeno-associated virus

Area of Science:

• Neuroscience
• Gene Therapy
• Molecular Biology

Background:

• Recombinant adeno-associated virus (rAAV) vectors are effective for gene transfer, enabling sustained gene expression.
• rAAVs have demonstrated success in preclinical models of central nervous system (CNS) disorders, with ongoing clinical trials.
• rAAV vector development has shown no significant toxicity in various applications.

Purpose of the Study:

• To review the application of rAAV vectors for gene transfer in the CNS.
• To discuss current methods for delivering rAAV vectors to the developing and adult mouse CNS.
• To highlight recent advancements in rAAV vector technology for blood-brain barrier penetration.

Main Methods:

• Review of existing literature on rAAV vector delivery to the CNS.
• Analysis of established and emerging techniques for CNS gene transfer.
• Examination of AAV vector properties related to blood-brain barrier crossing.

Main Results:

• rAAV vectors facilitate long-term gene expression in the CNS.
• Established delivery methods include intravascular injections in neonates and stereotaxic surgery in adults.
• Novel rAAV vectors can now permeate the blood-brain barrier, enabling intravascular delivery in adults.

Conclusions:

• rAAV vectors are valuable tools for CNS gene therapy with a good safety profile.
• Delivery strategies for rAAV vectors are adaptable to different developmental stages.
• The development of blood-brain barrier-penetrating rAAV vectors expands therapeutic possibilities for adult CNS disorders.